Form 4: Stoke Therapeutics' Chief Medical Officer, Barry Ticho, Executes Option and Sells Shares Under 10b5-1 Plan

Barry Ticho, Chief Medical Officer of Stoke Therapeutics, exercised stock options and sold 10,000 shares of common stock on July 1, 2024, under a pre-arranged 10b5-1 trading plan.

Summary

• On July 1, 2024, Barry Ticho, the Chief Medical Officer of Stoke Therapeutics, exercised options to acquire 10,000 shares of common stock at a price of $0.60 per share.
• Simultaneously, Ticho sold 10,000 shares of Stoke Therapeutics' common stock at a weighted average price of $13.7458 per share.
• These transactions were executed under a Rule 10b5-1 trading plan adopted on September 14, 2023.
• Following these transactions, Ticho directly owns 2,485 shares of common stock and holds options for 50,000 shares.

Sentiment

Score: 6

Explanation: The sentiment is neutral. The filing simply reports transactions under a pre-existing plan, with no explicit positive or negative implications for the company's outlook.

Positives

• The transactions were executed under a pre-arranged 10b5-1 trading plan, which can mitigate concerns about insider trading.

Risks

• Executive stock sales can sometimes be perceived negatively by investors, although the 10b5-1 plan mitigates this concern.

Future Outlook

The document does not contain specific forward-looking statements regarding the company's future performance.

Industry Context

Executive stock transactions are common in the biopharmaceutical industry and are often scrutinized by investors for insights into management's perspective on the company's prospects. The use of a 10b5-1 plan is a standard practice to avoid insider trading concerns.

Comparison to Industry Standards

• Executive compensation practices, including stock options and sales, are common across the biotechnology industry.
• Companies like Amgen, Biogen, and Vertex Pharmaceuticals also utilize stock options as part of their executive compensation packages.
• The vesting schedules and exercise prices are generally aligned with industry norms to incentivize long-term value creation.

Stakeholder Impact

• The transactions may have a minor impact on shareholders due to the change in ownership, but the pre-arranged nature of the trades mitigates potential concerns.

Key Dates